A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans
Jensen KP, DeVito EE, Herman AI, Valentine GW, Gelernter J, Sofuoglu M. A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. Neuropsychopharmacology 2015, 40: 2813-2821. PMID: 25948103, PMCID: PMC4864657, DOI: 10.1038/npp.2015.131.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCognition DisordersCotinineFemaleGenome-Wide Association StudyHeart RateHumansMaleMiddle AgedNerve Tissue ProteinsNeuropsychological TestsNicotineNicotinic AgonistsPolymorphism, Single NucleotideReceptors, NicotinicSmokingSubstance Withdrawal SyndromeSurveys and QuestionnairesConceptsAversive effectsHeavy smokingRisk allelesSmoking-related disordersAfrican American smokersCHRNA5-CHRNA3Doses of nicotineHigh nicotine doseNicotine administrationIntravenous doseNicotine effectsNicotine doseAmerican smokersWithdrawal severityOvernight abstinenceAcute responseAA subjectsCardiovascular reactivityCHRNB4 gene clusterNicotineEuropean AmericansAversive responsesAdministration sessionsSmokingCognitive performance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply